Monoclonal Antibodies for Alzheimer's Resources
In This Section
The American Academy of Neurology works to provide resources to help its members understand the current treatments available for mild cognitive impairment and Alzheimer's disease and how members can discuss with patients.
Drug Name/ Brand Name
|
Manufacturer | FDA Status | Infusion Frequency | Allowed Anticoagulation or Antiplatelet in Trial |
Aducanumab (Aduhelm)
|
Biogen |
Approved 2021 Under the accelerated approval |
Once every 4 weeks | Did not allow patients anticoagulation or antiplatelet therapy |
(Leqembi) |
Eisai | Granted traditional approval on July 6, 2023 | Bi-weekly | Allowed patients with anticoagulation or antiplatelet therapy |
(Kisunla) |
Eli Lilly |
Granted traditional approval on July 2, 2024 |
Once every 4 weeks |
Emerging Issues in Neurology
Emerging Issues in Neurology articles are designed to provide timely guidance to neurologists and other clinicians, derived from expert consensus about new or emerging issues, that have immediate implications for patient care but for which a formal evidence base is still evolving.
To help neurologists discuss these therapies with patients and caregivers, the AAN has developed this Emerging Issues in Neurology article:
Top Resources
- 2024 Annual Meeting Anti-amyloid Therapy Boot Camp Information
- Fall Conference on Demand 2023: Anti-amyloid Therapy Boot Camp
- CMS Fact Sheet on CED Data Submission Portal
- The AAN Requests New Coverage Options for Alzheimer's Drugs | June 12, 2023
- The AAN Submits Comments to CMS to Reconsider the NCD for Monoclonal Antibody Therapies | February 2, 2023
- Aducanumab Use in Symptomatic Alzheimer's Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee | February 23, 2022
- Decisions With Patients and Families Regarding Aducanumab in Alzheimer’s Disease, with Recommendations for Consent: AAN Position Statement | November 17, 2021
- NeuroBytes: Aducanumab for Alzheimer’s Disease | October 1, 2021
Recent News
- What's Next for Patients Treated With Aducanumab? (Neurology Today®) |May 16, 2024
- Despite FDA Delays, Experts Anticipate Donanemab Will Be Approved for Alzheimer's Disease (Neurology Today®) | April 18, 2024
- Lecanemab for Alzheimer's Disease Is It Worth It? (Neurology®) | April 9, 2024
- Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer's Disease (Neurology®) | April 9, 2024
- CMS Responds to AAN's NCD Request for Reconsideration | July 28, 2023
- FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval | July 6, 2023
- Press Release: AAN Submits National Coverage Determination Reconsideration Request to CMS | June 12, 2023
- The Advisory Committee unanimously voted that the results of the CLARITY AD trial provided evidence of clinical benefit for lecanemab for the treatment of Alzheimer’s disease | June 9, 2023
- CMS announces plan to ensure availability of new Alzheimer’s drugs | June 1, 2023
- How Donanemab Compares With Aducanumab in Amyloid Clearance (Neurology Today®) | April 20, 2023
- AAN Message on FDA Approval of Lecanemab | January 6, 2023
- What Health Care Systems Need to Do to Prepare for the Pipeline of New Alzheimer's Drugs (Neurology Today®) | December 1, 2022
- AAN summary of final coverage determination for aducanumab | April 7, 2022
- AAN, Geriatrics, and Nuclear Medicine request CMS cover beta amyloid PET | July 19, 2021
- National Coverage Determination (NCD) for Monoclonal Antibodies Treatment for Alzheimer’s Disease
Questions
Have questions or need additional resources?